Compare Cincinnati Financial Corporation (CINF) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Illumina, Inc. — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.58B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Cincinnati Financial Corporation and Illumina, Inc. are close in size by market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| CINF | ILMN | |
|---|---|---|
Market Cap | $26.58B | $29.12B |
Sector | Financials | Health |
52-Week High | $192.03 | $205.10 |
52-Week Low | $149.79 | $91.00 |
Enterprise Value | $25.71B | $30.48B |
Dividend Yield | 2.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
